Document is current
Any future updates will be listed below
-
Authors
Ragu, Sandrine
Droin, Nathalie
Matos-Rodrigues, Gabriel
Barascu, Aurélia
Caillat, Sylvain
Zarkovic, Gabriella
Siberchicot, Capucine
Dardillac, Elodie https://orcid.org/0000-0002-2069-8309
Gelot, Camille
Guirouilh-Barbat, Josée
Radicella, J. Pablo
Ishchenko, Alexander A.
Ravanat, Jean-Luc
Solary, Eric
Lopez, Bernard S. https://orcid.org/0000-0001-5088-0155
-
Funding
Funding for this research was provided by:
CIENCIACTIVA/CONCYTEC Doctoral Fellowship
Agence Nationale de la Recherche (ANR-18-CE44-0008)
Institut National Du Cancer (PRT-K16 057, 2018-1-PLBIO-07, PLBIO 2021)
Fondation ARC
- License Information
-
More Information
Article History
Received: 4 February 2022
Revised: 13 February 2023
Accepted: 21 February 2023
First Online: 3 March 2023
Competing interests
: The authors declare no competing interests.
: Blood samples from CMML patients with informed consent at inclusion and after 6 cycles of HU have been used (NCT02214407) based on a collaboration with the Groupe Francophone des Myélodyplasies (GFM). The study was performed in accordance with the Declaration of Helsinki.
